Cabozantinib did not increase survival of heavily treated patients with mCRPC, compared with prednisone.
Research emphasizes the need for nationwide refinements in the prostate cancer screening process.
In a small study, some men whose cancer progressed while on enzalutamide had a profound PSA response to pembrolizumab.
Adjusted odds ratio of prostate cancer significantly higher for MRI score than PSA.
Largest Asian series to date shows a 5-year biochemical recurrence-free survival rate of 76.4%.
Swedish researchers say their findings are more useful for counseling men with a family history of prostate cancer.
Study results strengthen researchers' arguments for further clinical trials evaluating the potential protective effect of statins.
Combination therapies targeting both mutations in the PI3K pathway and HER2 or hormone receptor overexpression should be evaluated, researchers say.
Preliminary findings suggest a field effect in prostate cancer.
Urologists in Australia less favorable toward adjuvant radiotherapy in 2015 vs 2012.
Odds of using this strategy are 2.7-fold greater vs community facilities.
Genetic testing results could help guide therapy for advanced prostate cancer.
For localized prostate cancer patients, hypofractionated radiation therapy at a dose of 60 Gy in fractions is effective.
About 10% of patients with clinically localized prostate cancer have lymphovascular invasion on their prostatectomy specimen.
Use of active surveillance increasing, active treatment decreasing for low-risk disease.
Reduced risk of positive surgical margins versus open prostatectomy for patients with pT2 disease only.
Superior median, 5-year OS for prostate RT plus ADT versus ADT alone in propensity score analyses.
Large prostates and bladder neck sparing also predict longer time to return of continence.
Findings emerge from a study of hypogonadal men who underwent radiation therapy, surgery, or active surveillance for prostate cancer.
Greater visceral adipose tissue volume and density are associated with a lower the risk of biochemical recurrence.
Radiation therapy also is associated with a greater likelihood of fractures.
Does not improve overall survival in metastatic castration-resistant prostate cancer.
Shows the strongest correlation between biochemical recurrence and subsequent systemic progression.
The odds of developing lethal prostate cancer were increased by 6.9 to 12.6 times for men aged 40 to 59 years with higher PSA values.
More effective tools are needed to support the long-term recovery of patients who survive cancer.
Three in 4 young or middle-aged patients receive aggressive therapies in the last months of life.
In prostate cancer, adjuvant docetaxel without hormone therapy did not improve biochemical disease-free survival after radical prostatectomy.
Transrectal ultrasound-guided (TRUS) prostate biopsy poorly detects and rules out clinically significant prostate cancer.
Adding enzalutamide to abiraterone acetate and leuprolide acetate does not appear to be effective for the treatment of localized high-risk prostate cancer.
A predictive model for chemotherapy toxicity found that 58% of patients experienced grade 3 toxicity or higher.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)